About Aiosyn
Aiosyn is a computational pathology company that develops AI-powered software solutions for cancer and kidney disease diagnosis and research. Founded as a spin-off from Radboudumc in the Netherlands, the company combines over 20 years of research experience with state-of-the-art artificial intelligence and engineering to create precision pathology solutions. Aiosyn's technology analyzes whole slide images using deep learning algorithms to enhance diagnostic accuracy and efficiency in digital pathology workflows. The company offers three main product lines: AiosynQC for automated quality control of digital histology slides, Aiosyn Mitosis Breast for identifying mitotic figures in breast cancer H&E sections, and the NephroPath platform for precise quantification of kidney lesion scores. These solutions are tightly integrated into existing pathology workflows, ensuring seamless adoption without disrupting established processes. Aiosyn serves clinical diagnostics laboratories, biopharma organizations, CROs, and AI/data providers. For clinical labs, the company provides certified diagnostic algorithms that augment pathologists' capabilities. For life sciences organizations, Aiosyn supports drug development by identifying novel pathology-based biomarkers and streamlining review processes. The company's modular software approach and close collaboration with pathology laboratories enable co-development of solutions that address real-world clinical needs while improving patient outcomes worldwide.
Mission & Story
Mission
At Aiosyn we are convinced that computational pathology empowers pathologists to make their work more accurate, efficient and effective. We develop software solutions that inject deep-learning algorithms into existing pathologist workflows to improve clinical decision-making.
Founding Story
Founded as a spin-off from Radboudumc, combining state-of-the-art AI research and engineering built upon 20+ years of research experience
Clinical Focus
Medical conditions and clinical areas addressed by Aiosyn.
Who It Serves
Milestones & Awards
Recent Milestones
IVDR-certified AI technology with Telemis (June 2025), expanded AI-powered quality control with incomplete scan detection (April 2025), Techcyte collaboration for Fusion platform integration (March 2025)
Key Partnerships
Social & Media
Latest Updates
Aiosyn and Pramana introduce real-time AI processing for kidney biopsy assessments
Aiosyn expands AI-powered quality control with incomplete scan detection
Aiosyn Mitosis Breast becomes the first AI-powered mitosis detection solution to achieve CE mark certification under IVDR
Aiosyn enhances its AI-powered quality control solution to detect white balance issues
Aiosyn’s kidney image analysis tools are now available on HistoWiz’s PathologyMap™
Company Details
- Headquarters
- Nijmegen, The Netherlands
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Cognoa
Cognoa is an early childhood development and pediatric behavioral health company developing digital diagnostics and therapeutics. Their flagship product, Canvas Dx, is the first FDA-authorized AI-powered diagnostic solution for autism in children ages 1.5-6 years, enabling diagnosis within days instead of months or years.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.